Day: March 22, 2023

COLUMBUS, Ohio, March 22, 2023 (GLOBE NEWSWIRE) — Worthington Industries, Inc. (NYSE: WOR) today reported net sales of $1.1 billion and net earnings of $46.3 million, or $0.94 per diluted share, for its fiscal 2023 third quarter ended February 28, 2023. In the third quarter of fiscal 2022, the Company reported net sales of $1.4 billion and net earnings of $56.3 million, or $1.11 per diluted share. Results in both the current and prior year quarter were impacted by certain unique items, as summarized in the table below. (U.S. dollars in millions, except per share amounts)    3Q 2023     3Q 2022      After-Tax     Per Share     After-Tax     Per Share  Net earnings   $ 46.3     $ 0.94     $ 56.3     $ 1.11  True-up of Level5 earnout accrual     (0.8 )     (0.02 )     –       –  Impairment and restructuring...

Fourth quarter results:Revenue and earnings growth driven by year-over-year pricing benefits Operating margin improved 330 basis points compared to prior year driven by gross margin improvement Year-over-year order declines moderated to 8% in fourth quarter compared to 17% in third quarterFiscal 2023 results:Company delivered 17% revenue growth and significant earnings improvement despite challenging environmentOutlook:First quarter guidance reflects continued year-over-year earnings improvement Company targets fiscal 2024 earnings growth driven largely by pricing benefitsGRAND RAPIDS, Mich., March 22, 2023 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) today reported fourth quarter revenue of $801.7 million, net income of $15.7 million, or $0.13 per share, and adjusted earnings per share of $0.19. ...

Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales Up 25% and 30% Respectively in Fourth Quarter 2022 vs Third Quarter 2022 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million Management to Host Conference Call Today, Wednesday, March 22, 2023 at 4:30 p.m. ET PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three and twelve months ended December 31, 2022 and provided a corporate update. “2022 was a turning point for Agile as we continued to advance revenue growth for Twirla and transformed and streamlined our operating model to reduce expenses,...

SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments. Key developments from Q4 2022 and year to date include: Initiation and First Patient Dosed in Phase 2 EVANGELINE Study – EVANGELINE (Endoxifen Versus exemestANe GosEreLIn), is our Phase 2 randomized non-inferiority study of (Z)-endoxifen compared to exemestane plus goserelin as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 ER+ / HER2- breast cancer. Participants receive neoadjuvant treatment for up to six months, followed by surgery. Several FDA-approved...

Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Ended Q4 with cash, cash equivalents, restricted cash and investments of $118.4M Company to host investor conference call and webcast today, Wednesday, March 22, at 4:30pm ET BURLINGTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2022 and provided a business update.  Business UpdateCommenced launch...

2022 total revenue of $8.2 million, an increase of 20% year-over-year 2022 total OvaSuiteSMvolume of 21,423 units, an increase 23% year-over-year Fourth quarter 2022 cash utilization of $7.1 million Conference Call and Webcast scheduled for today at 4:30 pm Eastern Time AUSTIN, Texas, March 22, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2022. “2022 was a year of tremendous transformation as we focused on our three strategic initiatives: growth, innovation, and operational excellence. While we exited the year a much leaner company in terms of headcount, we achieved many of our most important goals,...

Achieved consolidated Adjusted EBITDA profitability for first-time in LifeMD history Full Year 2022 consolidated revenue of $119.0 million, up 28% from the same year-ago period. Fourth quarter 2022 consolidated revenue of $28.1 million up 3% from the same year-ago period. This figure was impacted by a $2.9 million deferral of telehealth shipments. Adjusted EPS of $0.02, 107% improvement versus the prior year. Subsequent to year end, executed debt financing transaction with Avenue Capital, providing for up to $40 million of total capital and strengthening LifeMD’s long-term capital position. Full Year 2023 guidance of $140-$150 million in consolidated revenue and $12-$18 million of consolidated Adjusted EBITDA.NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company,...

REDWOOD CITY, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the fourth quarter and full year ended December 31, 2022. In 2022, Talis renewed its focus on the women’s and sexual health markets, where there is strong demand for infectious disease testing at the point of care. During the past several months, the Company continued to execute on aligning resources and reduced its monthly cash burn to targeted levels, extending expected cash runway into 2025. “Physicians in women’s and sexual health are eager to test patients at the point of care where treatment can be immediately prescribed...

– Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 – – Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis – – Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable – – Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar – – Conference call and webcast today at 4:30 p.m. ET – SAN JOSE, Calif., March 22, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended...